As part of a competitive landscape review we analyze the current competitive products and product pipelines. Additionally we review generic entry of products that will lose market exclusivity during your products’ development and commercialization lifecycle.
We perform extensive review, using a variety of informational resources to develop a comprehensive and actionable tool for your health outcomes, clinical, commercial, medical and corporate stakeholders. The final deliverable typically includes;
Disease burden (clinical, economic, and humanistic and animalistic) in various countries in order to help affiliates worldwide set the stage for supporting future products and to identify unmet need;
Current treatment options, existing treatment patterns, and clinical guidelines to evaluate standard of care and how new therapy options would be used;
Recommendations on the design of clinical trials and health outcomes studies, as applicable, based on regulatory requirements for FDA and EMEA;
Current treatment Pricing & Reimbursement status;
Evaluation of the key elements of scientific and economic data needed to develop successful reimbursement economic models and submissions based on HTA precedent and decisions;
Development of payer value propositions based on access challenges and opportunities.
